Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies
FMC-376 directly, rapidly, and completely blocks both active and inactive forms of KRASG12C to overcome…